BioForce Nanosciences Net debt/EBITDA
Was ist das Net debt/EBITDA von BioForce Nanosciences?
Net debt/EBITDA von BioForce Nanosciences Holdings, Inc. ist -13.80
Was ist die Definition von Net debt/EBITDA?
The net debt to earnings before interest, taxes, depreciation, and amortization (Net debt/EBITDA) ratio measures financial leverage and the company’s ability to pay off its debt. It shows how long it would take the company to pay off all its debt with operations at the current level.
The net debt to EBITDA ratio is calculated as Net debt divided by EBITDA. It is similar to the debt to EBITDA ratio, but cash and cash equivalents are subtracted in net debt.
Net debt = short-term debt + long-term debt - cash and cash equivalents
EBITDA = net income + interest expense + taxes + depreciation + amortization
Lower debt debt to EBITDA ratio indicates the company is not heavily indebted and should be able to repay its obligations. Alternatively, higher ratio indicated the company is excessively indebted. The ratio varies between industries as different industries have different capital requirements. Usually, the ratio should be compared to a benchmark or an industry average to determine the company’s credit risk. Generally, a net debt to EBITDA ratio above 4 or 5 is considered high.
Net debt/EBITDA von Unternehmen in Consumer Staples Sektor auf OTC im Vergleich zu BioForce Nanosciences
Was macht BioForce Nanosciences?
BioForce Nanosciences Holdings, Inc. focuses on providing natural vitamins, minerals, other nutritional supplements, powders, and beverages for individuals in various age ranges. The company offers private label products with distributors and manufacturing providers. It sells its nutrition supplements to retailers, sporting goods retailers, supermarkets, and mass merchandisers under the BioForce Eclipse brand, as well as through online and telemarketing. The company is based in Virginia Beach, Virginia.
Unternehmen mit net debt/ebitda ähnlich BioForce Nanosciences
- Isabella Bank hat Net debt/EBITDA von -13.86
- Sinosoft Technology hat Net debt/EBITDA von -13.85
- Capita Plc hat Net debt/EBITDA von -13.84
- EGL hat Net debt/EBITDA von -13.82
- Atlas Pearls Ltd hat Net debt/EBITDA von -13.82
- Excelsior Mining hat Net debt/EBITDA von -13.81
- BioForce Nanosciences hat Net debt/EBITDA von -13.80
- Greenbrook TMS hat Net debt/EBITDA von -13.79
- Neogenomics hat Net debt/EBITDA von -13.78
- Onto Innovation hat Net debt/EBITDA von -13.78
- CBTX Inc hat Net debt/EBITDA von -13.76
- Christopher & Banks hat Net debt/EBITDA von -13.75
- Patagonia Gold hat Net debt/EBITDA von -13.74